Table 3.
Clinical usefulness of developed MRI-PMs.
| Authors, [Ref.] | n | Repeat Biopsy |
csPCa | Sen. | Spe. | Avoided Biopsies |
Cut-Off | AUROC | DCA | CUC |
|---|---|---|---|---|---|---|---|---|---|---|
| Fang et al., 2016 [21] | 894 | 0 | 24.4 | 95 | 38 | 19.8 | 30 | 0.87 | 5 | NA |
| Kim et al., 2016 [22] | 339 | 35.4 | 34.0 | 95 | 20 | 15.1 | NA | 0.78 | NA | NA |
| Bjurlin et al., 2017 [23] | 288 | 0 | 33.6 | 95 | 56 | 42.2 | NA | 0.91 | NA | NA |
| Bjurlin et al., 2017 [23] | 171 | 100 | 18.1 | 95 | 40 | 33.9 | NA | 0.86 | NA | NA |
| Lee et al., 2017 [24] | 615 | 21.3 | 38.5 | 97.5 | 54.8 | 34.6 | 30 | 0.92 | NA | NA |
| Niu et al., 2017 [25] | 151 | 0 | 21.0 | 87.3 | 78.4 | 64.9 | 36 | 0.85 | NA | NA |
| Radtke et al., 2017 [26] | 660 | 0 | NA | 95 | 35 | NA | NA | 0.83 | 16 | NA |
| Radtke et al., 2017 [26] | 335 | 100 | NA | 95 | 25.5 | NA | NA | 0.81 | 12 | NA |
| Truong et al., 2017 [27] | 285 | 100 | 38.9 | 94.7 | 57.5 | 36.5 | 40 | 0.83 | 1 | NA |
| van Leeuwen et al., 2017 [28] | 393 | 12.5 | 37.9 | 93.9 | NA | 34.4 | 12.5 | 0.88 | 4 | NA |
| Alberts et al., 2018 [29] | 504 | 0 | 42.0 | 92 | NA | 24.0 | 15 | 0.84 | 10 | NA |
| Alberts et al., 2018 [29] | 504 | 100 | 29.0 | 95 | NA | 41.0 | 15 | 0.85 | 5 | NA |
| Huang et al., 2018 [30] | 231 | 100 | 25.5 | 95 | 63 | 48.0 | 21 | 0.92 | 10 | NA |
| Mehralivand et al., 2018 [31] | 400 | 55.2 | 48.3 | 96 | 54 | 30.0 | 15 | 0.84 | 10 | NA |
| Boesen et al., 2019 [32] | 876 | 0 | 40.0 | 96 | 60 | 38.0 | 15 | 0.89 | 5 | NA |
| Borque et al., 2019 [15] | 346 | 53.0 | 32.6 | 95 | 51 | 30.0 | 10 | 0.88 | 0.88 | Y |
| Chen et al., 2020 [33] | 257 | NA | 59.2 | 95 | 40 | 19.0 | NA | 0.84 | NA | NA |
| Noh et al., 2020 [34] | 300 | 28.3 | 34.0 | 95 | 52 | 30.1 | 10 | 0.86 | 10 | NA |
| Sakaguchi et al., 2021 [35] | 773 | 0 | 44.3 | 95 | 73 | 43.0 | 15 | 0.86 | 5 | NA |
| Kinnaird et al., 2022 [17] | 1885 | 62.0 | 40.0 | 95 | 32 | 21.2 | NA | 0.84 | NA | NA |
| Morote et al. 2022 [16] | 1486 | 26.1 | 36.9 | 95 | 56 | 40.0 | 15 | 0.90 | 12 | Y |
n = number of men; RB = percentage of repeat biopsies; csPCa = percentage of clinically significant prostate cancer; Sen = sensitivity; Spe = specificity; Repeat biopsy = percentage; Sen. = percent sensitivity; Esp. = percent specificity; Avoided biopsies = percentage; AUROC = area under Receiver operating characteristic curve; DCA = decision curve analysis; CUC = clinical utility curve; NA = not available.